Hearing implant company Cochlear has won US Food and Drug Administration approval for its Remote Check software which will allow hospitals and physicians to remotely monitor their patients.
Remote Check will now be rapidly rolled out via the internet, allowing healthcare providers to identify those in need of audiological care during the Covid-19 coronavirus pandemic.
The Remote Check telehealth patient assessment tool allows those who use a Cochlear Nucleus 7 sound processor to complete a series of hearing checks using a smart app and iOS device.
Results are then sent remotely to the patient’s clinic for review.
Cochlear CEO Dig Howitt said: “Remote care has been a core pillar of Cochlear’s long-term innovation strategy.
“With many people around the world now practising social distancing, Remote Check provides recipients with the ability to continue to access a level of care at a time when many clinics are closed to in-person visits.”
Cochlear will roll out the check first in the United States, followed by other markets including Canada, the UK and countries in Western Europe.
The technology has been tested in a pilot in five countries, allowing the FDA to expedite its approval process.
Subscribe to our free @AuManufacturing newsletter here.